Sorafenib Tosylate

甲苯磺酸索拉非尼

Report date: 2026/01/07 17:54:39
NMEFirst In Class

Base Information

Drug NameSorafenib Tosylate
Drug Alias NameSorafenib Tosilate对甲苯磺酸索拉非尼索拉菲尼Sorafenibum甲苯磺酸索拉菲尼 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsSerine/threonine-protein kinase B-raf inhibitorsVascular endothelial growth factor receptor 1 antagonists +[9] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[9] 
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Skin MelanomaPoorly Differentiated Thyroid Gland Carcinoma +[125] 
Global Approved IndicationsCarcinoma, Renal Cell
Approved Indications in ChinaCarcinoma, Renal Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2005/12/01
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOnyx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBayer Schering Pharma Ag Spółka Akcyjna Oddział W PolsceNational Cancer InstituteSt Petersburg State Pavlov Medical University +[6] 
Inactive CompaniesNovocure LtdDana-Farber Cancer InstituteSingapore Clinical Research Institute +[60] 
Active IndicationsMedullary thyroid cancer (MTC)Myeloproliferative DisordersMyelodysplastic Syndromes +[13] 
Inactive IndicationsSkin MelanomaPoorly Differentiated Thyroid Gland CarcinomaGastroesophageal Junction Neoplasms +[112] 

Other Information

ATC CodeL01EX02
Related LinksWikipediaDrugBankKEGG